ID: ALA4794420

Max Phase: Preclinical

Molecular Formula: C77H120N20O19

Molecular Weight: 1629.93

Molecule Type: Unknown

Associated Items:

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CC(C)C)C(=O)O

Standard InChI:  InChI=1S/C77H120N20O19/c1-8-43(6)62(72(112)94-57(75(115)116)38-42(4)5)95-69(109)56(40-46-22-26-48(99)27-23-46)93-71(111)59-19-14-36-97(59)74(114)53(17-12-34-84-77(81)82)90-65(105)49(16-11-33-83-76(79)80)88-70(110)58-18-13-35-96(58)73(113)52(15-9-10-32-78)89-63(103)44(7)85-64(104)51(29-31-61(101)102)87-68(108)55(39-45-20-24-47(98)25-21-45)92-67(107)54(37-41(2)3)91-66(106)50-28-30-60(100)86-50/h20-27,41-44,49-59,62,98-99H,8-19,28-40,78H2,1-7H3,(H,85,104)(H,86,100)(H,87,108)(H,88,110)(H,89,103)(H,90,105)(H,91,106)(H,92,107)(H,93,111)(H,94,112)(H,95,109)(H,101,102)(H,115,116)(H4,79,80,83)(H4,81,82,84)/t43-,44-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,62-/m0/s1

Standard InChI Key:  ACFFVPRDWLCNQO-KNQVYGPCSA-N

Associated Targets(Human)

Neurotensin receptor 1 1525 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Neurotensin receptor 2 296 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 1629.93Molecular Weight (Monoisotopic): 1628.9039AlogP: #Rotatable Bonds:
Polar Surface Area: Molecular Species: HBA: HBD:
#RO5 Violations: HBA (Lipinski): HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: CX LogP: CX LogD:
Aromatic Rings: Heavy Atoms: QED Weighted: Np Likeness Score:

References

1. Chartier M,Desgagné M,Sousbie M,Côté J,Longpré JM,Marsault E,Sarret P.  (2021)  Design, Structural Optimization, and Characterization of the First Selective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic.,  64  (4.0): [PMID:33538583] [10.1021/acs.jmedchem.0c01726]

Source